Cytori Therapeutics Inc (NASDAQ:CYTX) has been assigned a consensus recommendation of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $10.75.
Several equities research analysts have recently commented on CYTX shares. HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Cytori Therapeutics in a report on Tuesday, September 18th. Maxim Group reaffirmed a “hold” rating on shares of Cytori Therapeutics in a report on Thursday, November 15th. Finally, Zacks Investment Research downgraded Cytori Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 16th.
Shares of Cytori Therapeutics stock opened at $0.32 on Friday. The firm has a market capitalization of $4.29 million, a PE ratio of -0.05 and a beta of 1.98. Cytori Therapeutics has a fifty-two week low of $0.25 and a fifty-two week high of $5.18.
Cytori Therapeutics (NASDAQ:CYTX) last announced its earnings results on Wednesday, November 14th. The biotechnology company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.29). Cytori Therapeutics had a negative net margin of 366.48% and a negative return on equity of 202.61%. The company had revenue of $1.31 million for the quarter, compared to analysts’ expectations of $3.24 million. During the same period in the prior year, the company earned ($1.40) earnings per share. Analysts forecast that Cytori Therapeutics will post -0.99 EPS for the current year.
About Cytori Therapeutics
Cytori Therapeutics, Inc, a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types.
Recommended Story: Short Selling Stocks and Day Traders
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.